{"id":8692,"date":"2020-03-19T18:04:25","date_gmt":"2020-03-19T12:34:25","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8692"},"modified":"2021-07-24T12:57:50","modified_gmt":"2021-07-24T07:27:50","slug":"recent-pharma-happenings-for-sage-regeneron-johnson-and-johnson","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sage-regeneron-johnson-and-johnson","title":{"rendered":"Sage seeks to save depression drug; Regeneron aims clinical trial; J&J sets sights for COVID-19 trial"},"content":{"rendered":"\n

Sage Therapeutics seeking out to save flunked depression drug <\/strong><\/h2>\n\n\n\n

Sage Therapeutics has strategized on how to come back from the phase 3 failure of SAGE-217 in major depressive disorder<\/a>. The plan focuses on three short-term studies Sage contemplates that may enable it to bring the GABA receptor positive allosteric modulator to market in multiple indications.<\/p>\n\n\n\n

SAGE-217, aka zuranolone, failed a phase 3 trial late last year that made Sage halt on other studies as it tried to seek out a path forward for the asset. After having a meeting with the FDA, Sage has planned out an R&D strategy that lies somewhere between the best- and worst-case scenarios that have put forward by analysts.<\/p>\n\n\n\n

The plan is to commence three new clinical trials this year for trials of SAGE-217 in the postpartum depression<\/a> treatment and in two subsets of primary depressive disorder patients, namely those who need acute rapid response therapy or episodic therapy.<\/p>\n\n\n\n

Regeneron<\/strong> pharmaceuticals aims summer clinical trial for COVID-19 antibody<\/strong><\/h2>\n\n\n\n

Regeneron pharmaceuticals are known to be fast in the development of a promising monoclonal antibody triplet therapy for Ebola outbreak in Congo during 2018. It is under review by the U.S. FDA currently.<\/p>\n\n\n\n

Amid the ongoing coronavirus pandemic, the company has geared up again. The scientists of Regeneron have isolated hundreds of neutralizing antibodies against the SARS-CoV-2 virus from a humanized mouse model as well as from humans, who have recovered from COVID-19<\/a>.<\/p>\n\n\n\n

The aim is to choose the superior two antibodies for a cocktail therapy that can either be given to people who are at risk before exposure as a vaccine or as a treatment for those already affected.<\/p>\n\n\n\n

Regeneron targets to enter clinical studies by early summer if everything goes as scheduled.<\/p>\n\n\n\n

J&J sets sights on November for a COVID-19 vaccine trial<\/strong><\/h2>\n\n\n\n

Johnson & Johnson anticipates landing on a COVID-19<\/a> vaccine candidate by the end of the month, on the way to the clinical trials in early November. J&J will set up processes for the global production of the vaccine in order to have large quantities available for early next year.<\/p>\n\n\n\n

The giant is using the same vaccine platform that was used to develop its Ebola vaccine that will allow it to go very fast and with excellent information.<\/p>\n\n\n\n

Johnson & Johnson started work on a COVID-19 <\/a>vaccine in late January. It would take a parallel approach using at least five different virus constructs that would help it figure out which part of the virus can be used to make an effective vaccine.<\/p>\n","protected":false},"excerpt":{"rendered":"

Sage Therapeutics seeking out to save flunked depression drug  Sage Therapeutics has strategized on how to come back from the phase 3 failure of SAGE-217 in major depressive disorder. The plan focuses on three short-term studies Sage contemplates that may enable it to bring the GABA receptor positive allosteric modulator to market in multiple indications. […]<\/p>\n","protected":false},"author":1,"featured_media":8695,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2734,349,16942,639,18142,5789,1510,2100],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-8692","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-johnson-and-johnson","tag-latest-pharma-news","tag-major-depressive-disorder","tag-pharma-news","tag-postpartum-depression-treatment","tag-recent-pharma-news","tag-regeneron-pharmaceuticals","tag-sage-therapeutics","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"\nSage's depression drug; Regeneron's clinical trial; J&J COVID-19 trial<\/title>\n<meta name=\"description\" content=\"Johnson & Johnson started work on a COVID-19 vaccine in late January. It would take a parallel approach using at least five different virus constructs..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sage-regeneron-johnson-and-johnson\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sage's depression drug; Regeneron's clinical trial; J&J COVID-19 trial\" \/>\n<meta property=\"og:description\" content=\"Johnson & Johnson started work on a COVID-19 vaccine in late January. It would take a parallel approach using at least five different virus constructs..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sage-regeneron-johnson-and-johnson\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-19T12:34:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/19180217\/Pharma-news_19.03.2020-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sage's depression drug; Regeneron's clinical trial; J&J COVID-19 trial","description":"Johnson & Johnson started work on a COVID-19 vaccine in late January. It would take a parallel approach using at least five different virus constructs..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sage-regeneron-johnson-and-johnson","og_locale":"en_US","og_type":"article","og_title":"Sage's depression drug; Regeneron's clinical trial; J&J COVID-19 trial","og_description":"Johnson & Johnson started work on a COVID-19 vaccine in late January. It would take a parallel approach using at least five different virus constructs..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sage-regeneron-johnson-and-johnson","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-03-19T12:34:25+00:00","article_modified_time":"2021-07-24T07:27:50+00:00","og_image":[{"width":750,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/19180217\/Pharma-news_19.03.2020-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sage-regeneron-johnson-and-johnson","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sage-regeneron-johnson-and-johnson","name":"Sage's depression drug; Regeneron's clinical trial; J&J COVID-19 trial","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sage-regeneron-johnson-and-johnson#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sage-regeneron-johnson-and-johnson#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/19180217\/Pharma-news_19.03.2020-1.jpg","datePublished":"2020-03-19T12:34:25+00:00","dateModified":"2021-07-24T07:27:50+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Johnson & Johnson started work on a COVID-19 vaccine in late January. It would take a parallel approach using at least five different virus constructs..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sage-regeneron-johnson-and-johnson"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sage-regeneron-johnson-and-johnson#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/19180217\/Pharma-news_19.03.2020-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/19180217\/Pharma-news_19.03.2020-1.jpg","width":750,"height":482,"caption":"pharma news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/19180217\/Pharma-news_19.03.2020-1-300x193.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson and Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Major Depressive Disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Postpartum Depression Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regeneron Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sage Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Johnson and Johnson<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Major Depressive Disorder<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Postpartum Depression Treatment<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Regeneron Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Sage Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 19, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 19, 2020 6:04 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"pharma news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8692"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8692\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8695"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8692"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8692"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}